Bristol Myers Squibb Furnishes Q3 2025 Financial Results and Updated Guidance
Summary
Bristol Myers Squibb furnished its third quarter 2025 financial results on October 30, 2025, via an earnings press release (Ex. 99.1) and a presentation (Ex. 99.2). The company reported strong performance marked by continued growth portfolio momentum and pipeline advancements, alongside updated full-year guidance. * Q3 revenues increased 3% to $12.2 billion. * Growth Portfolio revenues rose 18% to $6.9 billion. * GAAP EPS was $1.08; non-GAAP EPS was $1.63. * 2025 revenue guidance raised to ~$47.5 billion to $48.0 billion.
Why It Matters
Investors should note the company's continued growth portfolio momentum and the raised 2025 revenue guidance to ~$47.5 billion to $48.0 billion (via Ex. 99.1), signaling positive operational performance and an improved outlook for the year.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how BMY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View BMY Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000014272
- Filing Date
- Thursday, October 30, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive